ReviewDalton transactions (Cambridge, England : 2003)2016
The Platin-X series: activation, targeting, and delivery.
Review in Dalton transactions (Cambridge, England : 2003), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 99 citations in OpenAlex.
- A Dual Action Platinum(IV) Complex with Self-assembly Property Inhibits Prostate Cancer through Mitochondrial Stress Pathway.ChemMedChem · 2024Article
- Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug-Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines.International journal of molecular sciences · 2023Article
- Bioactive Platinum(IV) Complexes Incorporating Halogenated Phenylacetates.Molecules (Basel, Switzerland) · 2022Article
- Potent Chlorambucil-Platinum(IV) Prodrugs.International journal of molecular sciences · 2022Article
- Genetically Engineered Nanoparticles of Asymmetric Triblock Polypeptide with a Platinum(IV) Cargo Outperforms a Platinum(II) Analog and Free Drug in a Murine Cancer Model.Nano letters · 2022Article
- Intersection of Inorganic Chemistry and Nanotechnology for the Creation of New Cancer Therapies.Accounts of materials research · 2022Article
- Interactions between mitochondria-damaging platinum(IV) prodrugs and cytochrome c.Dalton transactions (Cambridge, England : 2003) · 2022Article
- Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy.Frontiers in pharmacology · 2022Review
- The Strange Case: The Unsymmetric Cisplatin-Based Pt(IV) Prodrug [Pt(CHBioinorganic chemistry and applications · 2022Article
- Monofunctional Platinum(II) Anticancer Agents.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Zinc Complexes with Nitrogen Donor Ligands as Anticancer Agents.Molecules (Basel, Switzerland) · 2020Review
- Platinum-Triggered Bond-Cleavage of Pentynoyl Amide andJournal of the American Chemical Society · 2020Article
- Structurally Characterized BODIPY-Appended Oxidovanadium(IV) β-Diketonates for Mitochondria-Targeted Photocytotoxicity.ACS omega · 2020Article
- Response gene to complement-32 promotes cell survival via the NF-κB pathway in non-small-cell lung cancer.Experimental and therapeutic medicine · 2020Article
- trans-Platinum(II) Thionate Complexes: Synthesis, Structural Characterization, and in vitro Biological Assessment as Potent Anticancer Agents.ChemPlusChem · 2019Article
- A Multifunctional Hydrogel Delivers Gold Compound and Inhibits Human Lung Cancer Xenograft.Pharmaceutical research · 2019Article
- A Platinum(II) Complex of Heptamethine Cyanine for Photoenhanced Cytotoxicity and Cellular Imaging in Near-IR Light.Angewandte Chemie (International ed. in English) · 2018Article
- Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer.Oncotarget · 2018Article
- Platinum (II) complex-nuclear localization sequence peptide hybrid for overcoming platinum resistance in cancer therapy.ACS biomaterials science & engineering · 2018Article
- Protected and De-protected Platinum(IV) Glycoconjugates With GLUT1 and OCT2-Mediated Selective Cancer Targeting: Demonstrated Enhanced Transporter-Mediated Cytotoxic PropertiesFrontiers in chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Anticancer platinum (Pt) complexes have long been considered to be one of the biggest success stories in the history of medicinal inorganic chemistry. Yet there remains the hunt for the "magic bullet" which can satisfy the requirements of an effective chemotherapeutic drug formulation. Pt(iv) complexes are kinetically more inert than the Pt(ii) congeners and offer the opportunity to append additional functional groups/ligands for prodrug activation, tumor targeting, or drug delivery. The ultimate aim of functionalization is to enhance the tumor selective action and attenuate systemic toxicity of the drugs. Moreover, an increase in cellular accumulation to surmount the resistance of the tumor against the drugs is also of paramount importance in drug development and discovery. In this review, we will address the attempts made in our lab to develop Pt(iv) prodrugs that can be activated and delivered using targeted nanotechnology-based delivery platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.